GSA Capital Partners’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-13,739
| Closed | -$163K | – | 2018 |
|
|
2025
Q1 | $163K | Buy |
+13,739
| New | +$163K | 0.01% | 1440 |
|
|
2024
Q4 | – | Sell |
-10,667
| Closed | -$240K | – | 1893 |
|
|
2024
Q3 | $240K | Sell |
10,667
-15,134
| -59% | -$341K | 0.02% | 1337 |
|
|
2024
Q2 | $538K | Buy |
+25,801
| New | +$538K | 0.04% | 913 |
|
|
2024
Q1 | – | Sell |
-24,091
| Closed | -$249K | – | 1857 |
|
|
2023
Q4 | $249K | Sell |
24,091
-171,329
| -88% | -$1.77M | 0.02% | 1207 |
|
|
2023
Q3 | $1.54M | Buy |
195,420
+177,852
| +1,012% | +$1.4M | 0.13% | 195 |
|
|
2023
Q2 | $176K | Sell |
17,568
-54,931
| -76% | -$550K | 0.02% | 1306 |
|
|
2023
Q1 | $644K | Buy |
72,499
+44,532
| +159% | +$396K | 0.06% | 557 |
|
|
2022
Q4 | $307K | Buy |
+27,967
| New | +$307K | 0.04% | 916 |
|
|
2022
Q2 | – | Sell |
-15,963
| Closed | -$224K | – | 1679 |
|
|
2022
Q1 | $224K | Buy |
+15,963
| New | +$224K | 0.03% | 1106 |
|